These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28714375)

  • 1. The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.
    Fiala O; Pitule P; Hosek P; Liska V; Sorejs O; Bruha J; Vycital O; Buchler T; Poprach A; Topolcan O; Finek J
    Tumour Biol; 2017 Jul; 39(7):1010428317709283. PubMed ID: 28714375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer.
    Li H; Dai S; Zhen T; Shi H; Zhang F; Yang Y; Kang L; Liang Y; Han A
    Eur J Cancer; 2014 Apr; 50(6):1207-21. PubMed ID: 24412052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
    Ulivi P; Canale M; Passardi A; Marisi G; Valgiusti M; Frassineti GL; Calistri D; Amadori D; Scarpi E
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
    Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
    Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression levels of miR-143-3p and -424-5p in colorectal cancer and their clinical significance.
    Sahami-Fard MH; Kheirandish S; Sheikhha MH
    Cancer Biomark; 2019; 24(3):291-297. PubMed ID: 30883340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.
    Mlcochova J; Faltejskova-Vychytilova P; Ferracin M; Zagatti B; Radova L; Svoboda M; Nemecek R; John S; Kiss I; Vyzula R; Negrini M; Slaby O
    Oncotarget; 2015 Nov; 6(36):38695-704. PubMed ID: 26497852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer.
    Kiss D; Machackova T; Souckova K; Fabian P; Krepelkova I; Svoboda M; Kiss I
    In Vivo; 2021; 35(5):2809-2814. PubMed ID: 34410972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
    Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC
    BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
    Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet JB; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem JL; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
    Clin Cancer Res; 2014 Jun; 20(12):3338-47. PubMed ID: 24771647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding.
    Baltruskeviciene E; Schveigert D; Stankevicius V; Mickys U; Zvirblis T; Bublevic J; Suziedelis K; Aleknavicius E
    BMC Cancer; 2017 Sep; 17(1):607. PubMed ID: 28863773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.
    Stiegelbauer V; Vychytilova-Faltejskova P; Karbiener M; Pehserl AM; Reicher A; Resel M; Heitzer E; Ivan C; Bullock M; Ling H; Deutsch A; Wulf-Goldenberg A; Adiprasito JB; Stoeger H; Haybaeck J; Svoboda M; Stotz M; Hoefler G; Slaby O; Calin GA; Gerger A; Pichler M
    Clin Cancer Res; 2017 Sep; 23(17):5255-5266. PubMed ID: 28533224
    [No Abstract]   [Full Text] [Related]  

  • 13. miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR.
    Li W; Chang J; Wang S; Liu X; Peng J; Huang D; Sun M; Chen Z; Zhang W; Guo W; Li J
    Oncotarget; 2015 Sep; 6(27):24448-62. PubMed ID: 26259252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
    Lereclus E; Tout M; Girault A; Baroukh N; Caulet M; Borg C; Bouché O; Ternant D; Paintaud G; Lecomte T; Raoul W
    BMC Cancer; 2017 Mar; 17(1):220. PubMed ID: 28347290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
    Kiss I; Mlcochova J; Bortlicek Z; Poprach A; Drabek J; Vychytilova-Faltejskova P; Svoboda M; Buchler T; Batko S; Ryska A; Hajduch M; Slaby O
    Anticancer Res; 2016 Sep; 36(9):4955-9. PubMed ID: 27630355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer.
    Christensen LL; Tobiasen H; Holm A; Schepeler T; Ostenfeld MS; Thorsen K; Rasmussen MH; Birkenkamp-Demtroeder K; Sieber OM; Gibbs P; Lubinski J; Lamy P; ; Laurberg S; Oster B; Hansen KQ; Hagemann-Madsen R; Byskov K; Ørntoft TF; Andersen CL
    Int J Cancer; 2013 Jul; 133(1):67-78. PubMed ID: 23280316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening and preliminary validation of miRNAs with the regulation of hTERT in colorectal cancer.
    Qin YZ; Xie XC; Liu HZ; Lai H; Qiu H; Ge LY
    Oncol Rep; 2015 Jun; 33(6):2728-36. PubMed ID: 25845814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of microRNA-409-3p promotes aggressiveness and metastasis in colorectal cancer: an indication for personalized medicine.
    Liu M; Xu A; Yuan X; Zhang Q; Fang T; Wang W; Li C
    J Transl Med; 2015 Jun; 13():195. PubMed ID: 26084278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A.
    Yin Y; Zhang B; Wang W; Fei B; Quan C; Zhang J; Song M; Bian Z; Wang Q; Ni S; Hu Y; Mao Y; Zhou L; Wang Y; Yu J; Du X; Hua D; Huang Z
    Clin Cancer Res; 2014 Dec; 20(23):6187-99. PubMed ID: 25294901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.